Adaptive Biotechnologies Reports Q3 2026 Revenue Growth and Raised Full-Year MRD Guidance
Adaptive Biotechnologies (ADPT) reported strong third-quarter results for fiscal year 2026, highlighted by $83.9 million in total revenue, representing a 39% year-over-year increase when excluding prior-year Genentech milestone impacts. The company achieved GAAP net income of $2.8 million and reached total company profitability with free cash flow of $7.7 million. Growth was driven significantly by its MRD (Minimal Residual Disease) segment, which saw 44% revenue growth. Reflecting strong momentum, management raised its full-year MRD revenue guidance to a range of $276 million to $286 million and increased clinical volume growth projections to approximately 42%. While the company is seeing increased adoption in pharma sequencing and community practices, CFO Kyle Piskel noted potential pressure on average selling prices (ASP) due to Medicare episode rate limits as patient monitoring frequency increases.
Topics: EBITDA Net Income Pharma Backlog Revenue Growth Testing Volume